Preclinical Hepatitis C Programs

Program Discovery Preclinical Phase 1 Phase 2 Phase 3
Hepatitis C CC-2850
(Pan-genotypic NS5B Nuc)
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Hepatitis C CC-2069
(Pan-genotypic NS5A inhibitor)
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

CC-2859

CC-2850 is a novel pan-genotypic nucleoside prodrug with similar HCV potency and cytotoxicity profile as sofosbuvir and delivers higher levels of the active metabolite (nucleoside 5'-triphosphate) compared to sofosbuvir.

CC-2069

CC-2069 is a novel highly potent, pan-genotypic, NS5A inhibitor that produces an active metabolite (also a pM HCV inhibitor).